Thymoma · 6 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Octreotide and Prednisone Variant #01 | — | R 248 577 | 30d | — | — | — | — | — |
Sunitinib monotherapy Variant #05 | — | R 33 433 | 28d | ~4.0 mo | — | ~5 | ~R 167 165 PFS proxy · indirect | 2 |
Everolimus monotherapy Variant #01 | — | R 18 360 | 28d | ~6.0 mo | ~18.1 mo | ~7 | ~R 128 518 PFS proxy · indirect | 15 |
Capecitabine and Gemcitabine Variant #06 | — | R 17 897 | 56d | — | ~7.9 mo | — | — | 6 |
Ifosfamide monotherapy N/A - secondary systemic drug | — | R 9 835 | 28d | ~4.0 mo | ~8.4 mo | ~5 | ~R 49 173 PFS proxy · indirect | 2 |
Octreotide monotherapy Variant #04 | — | R 5 799 | — | — | — | — | — | — |
6 of 6 regimens shown